RBM17 and prostate cancer: Taken together, given its small size yet excellent predictive power, we concluded [AQP1, SEPT8, RBM17, TRIM47, VPS25] as a novel, practical biomarker panel for predicting response to 17-AAG treatment in prostate cancer.